Comparative Pharmacology
Head-to-head clinical analysis: LIPIDIL versus LIPOFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPIDIL versus LIPOFEN.
LIPIDIL vs LIPOFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIPIDIL (fenofibrate) is a fibric acid derivative that activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), leading to increased lipolysis and clearance of triglyceride-rich particles, and increased synthesis of apolipoproteins A-I and A-II.
Lipofen (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It activates PPARα, which increases lipolysis and elimination of triglyceride-rich particles from plasma by stimulating lipoprotein lipase activity and reducing apolipoprotein C-III production. This leads to decreased triglyceride levels and increased HDL cholesterol.
130 mg orally once daily.
For hypertriglyceridemia: 67-134 mg (as fenofibric acid) orally three times daily with meals. Maximum dose 200 mg/day.
None Documented
None Documented
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This supports once-daily dosing; steady-state is achieved after ~5 days.
5-7 hours (prolonged in renal impairment; may exceed 24 hours in severe CKD).
Primarily renal excretion of glucuronide conjugates; approximately 70% of a single oral dose is recovered in urine (mostly as fenofibric acid glucuronide), and about 6% is excreted in feces.
Primarily renal (90% as unchanged drug), with <5% fecal.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic